Cargando…

Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19

IgM and IgG antibodies to the SARS-CoV-2 virus are detected in subjects who have recovered from COVID-19; IgM antibodies persist in a 1/3 of infected subjects up to 12 months from the moment of the disease, while IgG antibodies are present in the vast majority of cases (97%; medium and high levels a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kombarova, S. Yu., Aleshkin, A. V., Novikova, L. I., Bochkareva, S. S., Zatevalov, A. M., Mekhtiev, E. R., Mizaeva, T. E., Basov, A. A., Borisova, O. Yu., Likhanskaya, E. I., Voropaeva, E. A., Urban, Yu. N., Mitrokhin, S. D., Shkoda, A. S., Gushchin, V. A., Sinyavin, A. E., Nikiforova, M. A., Lebedin, Yu. S., Karaulov, A. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628323/
https://www.ncbi.nlm.nih.gov/pubmed/36322302
http://dx.doi.org/10.1007/s10517-022-05620-1
_version_ 1784823170623078400
author Kombarova, S. Yu.
Aleshkin, A. V.
Novikova, L. I.
Bochkareva, S. S.
Zatevalov, A. M.
Mekhtiev, E. R.
Mizaeva, T. E.
Basov, A. A.
Borisova, O. Yu.
Likhanskaya, E. I.
Voropaeva, E. A.
Urban, Yu. N.
Mitrokhin, S. D.
Shkoda, A. S.
Gushchin, V. A.
Sinyavin, A. E.
Nikiforova, M. A.
Lebedin, Yu. S.
Karaulov, A. V.
author_facet Kombarova, S. Yu.
Aleshkin, A. V.
Novikova, L. I.
Bochkareva, S. S.
Zatevalov, A. M.
Mekhtiev, E. R.
Mizaeva, T. E.
Basov, A. A.
Borisova, O. Yu.
Likhanskaya, E. I.
Voropaeva, E. A.
Urban, Yu. N.
Mitrokhin, S. D.
Shkoda, A. S.
Gushchin, V. A.
Sinyavin, A. E.
Nikiforova, M. A.
Lebedin, Yu. S.
Karaulov, A. V.
author_sort Kombarova, S. Yu.
collection PubMed
description IgM and IgG antibodies to the SARS-CoV-2 virus are detected in subjects who have recovered from COVID-19; IgM antibodies persist in a 1/3 of infected subjects up to 12 months from the moment of the disease, while IgG antibodies are present in the vast majority of cases (97%; medium and high levels antibodies were registered in 85% of cases). By the 12th month, 40% of those who recovered still have a very high level of IgG antibodies to the S-protein (>500 BAU/ml). In the feces, urine, and blood serum of patients with long-term persistent IgM antibodies, no coronavirus antigens were detected. After vaccination with the Gam-COVID-Vac vaccine, IgG antibodies to the S-protein are detected in 100% of cases and remain at a high level for 4 months, by the 5-6th month, the level of antibodies decreases. During revaccination, the level of IgG antibodies to S-protein reaches high values earlier than during primary vaccination, and remains high for 4 months (observation period). The blood sera of recovered and vaccinated patients have a high virus-neutralizing activity (at least 1:80), while its level is somewhat higher in recovered patients.
format Online
Article
Text
id pubmed-9628323
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-96283232022-11-02 Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19 Kombarova, S. Yu. Aleshkin, A. V. Novikova, L. I. Bochkareva, S. S. Zatevalov, A. M. Mekhtiev, E. R. Mizaeva, T. E. Basov, A. A. Borisova, O. Yu. Likhanskaya, E. I. Voropaeva, E. A. Urban, Yu. N. Mitrokhin, S. D. Shkoda, A. S. Gushchin, V. A. Sinyavin, A. E. Nikiforova, M. A. Lebedin, Yu. S. Karaulov, A. V. Bull Exp Biol Med Immunology and Microbiology IgM and IgG antibodies to the SARS-CoV-2 virus are detected in subjects who have recovered from COVID-19; IgM antibodies persist in a 1/3 of infected subjects up to 12 months from the moment of the disease, while IgG antibodies are present in the vast majority of cases (97%; medium and high levels antibodies were registered in 85% of cases). By the 12th month, 40% of those who recovered still have a very high level of IgG antibodies to the S-protein (>500 BAU/ml). In the feces, urine, and blood serum of patients with long-term persistent IgM antibodies, no coronavirus antigens were detected. After vaccination with the Gam-COVID-Vac vaccine, IgG antibodies to the S-protein are detected in 100% of cases and remain at a high level for 4 months, by the 5-6th month, the level of antibodies decreases. During revaccination, the level of IgG antibodies to S-protein reaches high values earlier than during primary vaccination, and remains high for 4 months (observation period). The blood sera of recovered and vaccinated patients have a high virus-neutralizing activity (at least 1:80), while its level is somewhat higher in recovered patients. Springer US 2022-11-02 2022 /pmc/articles/PMC9628323/ /pubmed/36322302 http://dx.doi.org/10.1007/s10517-022-05620-1 Text en © Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Immunology and Microbiology
Kombarova, S. Yu.
Aleshkin, A. V.
Novikova, L. I.
Bochkareva, S. S.
Zatevalov, A. M.
Mekhtiev, E. R.
Mizaeva, T. E.
Basov, A. A.
Borisova, O. Yu.
Likhanskaya, E. I.
Voropaeva, E. A.
Urban, Yu. N.
Mitrokhin, S. D.
Shkoda, A. S.
Gushchin, V. A.
Sinyavin, A. E.
Nikiforova, M. A.
Lebedin, Yu. S.
Karaulov, A. V.
Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19
title Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19
title_full Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19
title_fullStr Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19
title_full_unstemmed Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19
title_short Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19
title_sort features of the humoral response to infection, vaccination, and revaccination during covid-19
topic Immunology and Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628323/
https://www.ncbi.nlm.nih.gov/pubmed/36322302
http://dx.doi.org/10.1007/s10517-022-05620-1
work_keys_str_mv AT kombarovasyu featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT aleshkinav featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT novikovali featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT bochkarevass featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT zatevalovam featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT mekhtiever featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT mizaevate featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT basovaa featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT borisovaoyu featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT likhanskayaei featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT voropaevaea featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT urbanyun featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT mitrokhinsd featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT shkodaas featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT gushchinva featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT sinyavinae featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT nikiforovama featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT lebedinyus featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19
AT karaulovav featuresofthehumoralresponsetoinfectionvaccinationandrevaccinationduringcovid19